Vir Biotechnology, Inc.

As of August 18, 2025, Vir Biotechnology, Inc. shows a mildly bearish trend with mixed signals from moving averages and indicators, and has underperformed the S&P 500 with a year-to-date return of -29.43%.

As of May 4, 2023, Vir Biotechnology, Inc. is considered risky and overvalued due to its negative P/E ratio, low Price to Book Value of 0.72, and an EV to EBITDA ratio of 0.23, alongside disappointing stock performance with a year-to-date return of -29.43% and a five-year return of -84.17%.

As of May 4, 2023, Vir Biotechnology, Inc. is considered overvalued and risky due to poor financial metrics, including a negative return on equity of -49.94%, and has significantly underperformed the S&P 500 with a year-to-date return of -31.20%.

As of June 20, 2025, Vir Biotechnology, Inc. shows a mildly bearish trend with mixed signals from indicators, including a mildly bullish MACD on weekly and monthly time frames, while Bollinger Bands and moving averages indicate bearish conditions.

As of March 2022, the management team of Vir Biotechnology, Inc. includes Dr. Vicki Sato (Independent Chairman), Dr. George Scangos (President and CEO), and several Independent Directors: Mr. Jeffrey Hatfield, Ms. Janet Napolitano, Mr. Robert More, Mr. Robert Nelsen, and Mr. Dipchand Nishar.

Vir Biotechnology, Inc. is a clinical-stage immunology company focused on developing treatments for serious infectious diseases. As of March 2025, it has a market cap of $705.01 million, with net sales of $3 million and a net loss of $121 million.

As of Jun 18, Vir Biotechnology, Inc. has a market capitalization of 705.01 million and reported net sales of 20.86 million, with a net profit of -577.66 million. Shareholder's funds are 1,150.38 million, and total assets are 1,423.59 million.